Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond

Authors:

Abstract
Tezepelumab, a biologic therapy for severe asthma, blocks TSLP activity, subsequently downregulating multiple type 2 inflammatory pathways and reducing airway hyperresponsiveness via eosinophil-independent effects https://bit.ly/3XGpaV3
Funding Information
  • Amgen
  • AstraZeneca

This publication has 10 references indexed in Scilit: